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The burden of COVID-19
It has been 18 months since the World Health Organization declared 
SARS-CoV-2 disease (COVID-19) a pandemic, with 197.4 million 
cases and 4.22 million COVID-19 deaths reported by 1  August 
2021.[1] The number of documented COVID-19 cases and deaths, 
however, probably grossly under-estimates the burden of COVID-19, 
particularly in low- and middle-income countries (LMICs) where 
access to SARS-CoV-2 testing remains constrained. South Africa (SA) 
has the highest testing rate for SARS-CoV-2 in Africa (cumulative 248 
per 1 000 population), which is 1/14th of the cumulative testing rate in 
the UK (3 516 per 1 000 population).[1] Corroborating that the burden 
of SARS-CoV-2 infection has been under-estimated in SA is the 
sero-survey (testing for antibody to determine past infection) which 
reported that 32 - 63% of blood donors across four provinces in SA had 
been infected by SARS-CoV-2 prior to the current resurgence (third 
wave).[2] Consequently, the 2.39 million recorded COVID-19 cases 
(4% of the population) probably represents 1/10th of the SARS-CoV-2 
infections that have occurred in SA. The immense force of SARS-
CoV-2 infection experienced in SA transpired despite attempts by the 
government to limit the rate of its spread through highly restrictive 
restrictions, which massively impacted on the economy and livelihoods 
of people.
Similarly, the burden of reported COVID-19 deaths is probably an 
under-estimate globally, particularly in LMICs with fragile healthcare 
systems and tenuous vital registration registries unable to track trends 
in mortality in real time. In India alone, modelling of excess deaths 
attributable to COVID-19 (i.e. deaths over and above what would be 
expected based on historical averages) using different data sources 
and case scenarios estimates that there had been 3.4 - 4.9 million 
COVID-19 deaths (crude estimated death rate 261 - 360 per 100 000 
population) by July 2021, which is approximately 10-fold higher than 
the 423 000 documented deaths (crude estimated death rate 31 per 
100  000) by July 2021.[3] In SA, the modelled excess mortality since 
May 2020 has been strikingly synchronous with documented COVID-
19 deaths, indicating that the vast majority of the excess deaths were 
due to COVID-19. This is corroborated by data from the Western 
Cape, the province with the most robust public health surveillance and 
healthcare system in the country, where the recorded COVID-19 and 
modelled excess deaths are closely aligned. In contrast, there is a huge 
discrepancy between recorded and modelled excess deaths in Gauteng, 
where 25% of the SA population lives.[4] The death toll of COVID-19 
in SA as of July 2021 is likely to be closer to 214 200 (crude mortality 
rate 360 per 100 000 population aged >1 year) rather than the under-
estimated 70 388 (118 per 100 000) recorded deaths.
Given this background, it is important to reflect on the success 
against and challenges posed by COVID-19, to chart a sustainable 
pathway forward with the goal of minimising further direct and 
indirect suffering due to COVID-19 in SA and globally.
Evolution of SARS-CoV-2 and 
implications for herd immunity
In the absence of ability to contain the spread of SARS-CoV-2 in the 
vast majority of countries, herd immunity was widely envisioned and 
propagated as the endgame for COVID-19. A minority of scientists 
and politicians advocated for minimal interventions and to allow 
SARS-CoV-2 infections to run their course, in the misguided belief 
that it would result in a herd immunity threshold being reached. 
Such a strategy was advocated oblivious to the cost of human life that 
would have transpired. Also, whether herd immunity would result 
through natural infection alone was doubtful. With the ongoing 
evolution of the virus, including mutations that made it more 
infectious, more transmissible and relatively resistant to immunity 
induced by past infection or by first-generation COVID-19 vaccines, 
herd immunity is now an aspiration unlikely to materialise.
Mutations of SARS-CoV-2 have been associated with increased transmissibility and occasionally reduced sensitivity to neutralising antibody 
activity induced by past ancestry virus infection or current COVID-19 vaccines. Nevertheless, COVID-19 vaccines have consistently 
demonstrated high efficacy and effectiveness against COVID-19 severe disease, hospitalisation and death, including disease caused by 
designated variants of concern. In contrast, COVID-19 vaccines are more heterogeneous in reducing the risk of infection and mild COVID-
19, and are modestly effective in interrupting virus transmission. Ongoing mutations of SARS-CoV-2 resulting in increased transmissibility 
and relative evasion of neutralising antibody activity induced by past virus infection or COVID-19 vaccines are likely. The duration of 
protection induced by COVID-19 vaccines is modelled to be relatively short in protecting against infection and mild COVID-19, but is 
likely to be 2 - 3 years against severe disease. Current experience from the UK and Israel demonstrates that even with high levels of COVID-
19 vaccine coverage (>85% of the adult population), resurgences with new variants of concern remain a strong probability. Nevertheless, 
such resurgences are not mirrored by high rates of hospitalisation and death compared with what was experienced in relatively COVID-19 
vaccine-naive populations. Even though COVID-19 vaccines are unlikely to result in a herd immunity state, their ability to protect against 
severe COVID-19 and death could allow for a return to normalcy once a large enough proportion of the adult population in a country has 
been vaccinated.
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The dynamic mutations of SARS-CoV-2 over the past 6 - 8 months, 
coupled with the now inequitable and sluggish roll-out of COVID-
19 vaccines, call into question whether herd immunity can be 
attained even with acceleration of COVID-19 vaccine coverage. 
Reaching a herd immunity threshold is more than balancing a 
simple mathematical equation (p1 = 1 – 1/R0). In this equation, p1 
is the proportion of immune individuals, i.e. who are no longer 
at risk of being infected by the micro-organism (or at least able 
to clear it very quickly without onward transmission to others). 
The reproductive rate (R0) is the average number of individuals 
who will be infected by the micro-organism in a fully susceptible 
population by a new case. Over time, as there is a build-up of 
people who develop immunity against infection by the virus (which 
is very different to being protected against COVID-19 or severe 
disease), the effective reproductive rate gravitates to <1 (i.e. every 
new case will on average infect less than one other person). The 
requirement for the effective reproductive rate being sustained at 
<1 in the absence of other interventions that might affect the rate 
of transmission of the micro-organism, such as social distancing, 
wearing of face masks and avoiding mass gatherings, is when herd 
immunity can be declared.
Challenges posed by COVID-19 include the fact that the 
transmissibility and infectiousness of SARS-CoV-2 have increased 
over time owing to evolving mutations of the spike protein. The R0 
for the Wuhan strain of SARS-CoV-2 was estimated to be 2.5 - 4.0.[5] 
The R0 is dynamic and influenced by local factors such population 
density, population structure and main sources of transmission, 
living environment conditions and patterns of social interaction. 
Also, implementation of restrictions on social activities, adoption of 
masking and other non-pharmacological interventions would affect 
the virus transmission rate. SARS-CoV-2 mutations that resulted in 
variants of concern such as the delta variant now dominate almost 
globally, and are estimated to be two-fold more transmissible than the 
ancestry virus.[6] Hence, whereas the simple mathematical equation 
predicted that herd immunity could be reached once 67% (67% = 
1 – (1 ÷ 3) × 100%, assuming R0 = 3) of the population developed 
adequate immunity against infection by the ancestry virus, the 
threshold would increase to 84% (assuming R0 = 6) for the delta 
variant.
SARS-CoV-2 and immune evasion
The need to recalibrate our expectations of whether herd immunity 
can be attained, the role of COVID-19 vaccines and the future of 
the COVID-19 pandemic was prominently highlighted following 
the identification of the beta variant in SA in November 2020. The 
evolution of the beta and other variants of concern (such as alpha, 
gamma and delta) emerged partly as a result of build-up of immune 
pressure through natural acquired SARS-CoV-2 infections and 
prior to the widespread use of COVID-19 vaccines. An increased 
prevalence of antibody against SARS-CoV-2 induced by ongoing 
virus transmission and sluggish roll-out of COVID-19 vaccine in 
most parts of the world is likely to facilitate further mutations as the 
virus continues to adapt.
The relative resistance of the beta variant to in vitro neutralising 
activity of antibody induced by ancestry SARS-CoV-2 infection[7] 
provided the first signal of challenges faced in the agenda to achieve a 
herd immunity state. A longitudinal cohort study in SA demonstrated 
that past infection by the ancestry virus did not provide protection 
against SARS-CoV-2 infection by the beta variant.[8] This was 
compounded by findings of the University of Oxford/AstraZeneca 
non-replicating simian adenovirus spike-protein vaccine (AZD1222) 
in SA, which despite demonstrating 75% protection against mild to 
moderate COVID-19 caused by the ancestry virus 14 days after a 
single dose, showed no efficacy against mild to moderate beta-variant 
COVID-19 following two doses of the vaccine.[9] The reduction 
in vaccine-induced neutralising antibody activity against the beta 
variant has been demonstrated for all COVID-19 vaccines, albeit 
varying between vaccines.[10,11]
A definitive correlate of protection against SARS-CoV-2 infection 
is yet to be established. Nevertheless, the magnitude of vaccine-
induced fold increase in in vitro neutralising (correlation coefficient = 
0.79) and binding antibodies (correlation coefficient = 0.93) is 
strongly associated with observed efficacy against COVID-19 study 
endpoints enriched for mild to moderate COVID-19.[12] Notably, 
COVID-19 vaccine-induced neutralising antibody activity is variably 
affected by different variants of concern. In SA, the beta variant 
that dominated during the second COVID-19 wave was shown to 
have near to complete resistance to antibody-neutralising activity 
induced by past infection by the ancestry virus and the AstraZeneca 
COVID-19 vaccine,[4,5] as well as greatly diminished neutralising 
activity induced by messenger RNA (Pfizer-Biontech and Moderna) 
COVID-19 vaccines compared with the neutralising activity against 
the ancestry virus.[6]
The differences in magnitude of COVID-19-induced neutralising 
antibody against the beta variant are likely to contribute to varying 
effectiveness against mild to moderate COVID-19, with the Pfizer-
Biontech vaccine (BNT162b2), which induces a high magnitude of 
neutralising antibody against the ancestry virus, able to overcome 
some of the resistance of the beta variant and consequently reporting 
100% efficacy against the beta variant.[13]
Although the currently dominating delta variant is more susceptible 
to vaccine-induced neutralising antibody activity compared with the 
beta variant, it too shows intermediary resistance to vaccine-induced 
neutralising antibody compared with the ancestry virus.[10,14]
Whereas variant-specific neutralising antibody activity appears to 
be associated with efficacy against mainly mild to moderate COVID-
19,[12,15] an immunological biomarker associated with protec tion against 
severe COVID-19 remains to be ascertained. Despite near abrogation 
of AZD1222-induced in vitro neutralising antibody activity following 
two doses of the vaccine, vaccination with the AZD1222 vaccine in a 
Syrian hamster SARS-CoV-2 challenge model protected against any 
lung pathology following beta-variant challenge, despite not preventing 
viral replication in the nose.[16] Furthermore, vaccine effectiveness 
for the AstraZeneca vaccine against COVID-19 hospitalisation or 
death due to the beta or gamma variants, both of which share the 
E484K mutation, was 83% (95% confidence interval  66 - 92).[17] 
These data indicate that the magnitude of neutralising and binding 
antibody is strongly correlated to protection against SARS-CoV-2 
infection and mild to moderate disease. In contrast, either much lower 
concentrations of neutralising antibody may be required to protect 
against severe COVID-19, or – more compelling – protection against 
severe COVID-19 is possibly mediated by T-cell immunity. The CD4+ 
and CD8+ (natural killer cell) responses induced by the AZD1222 
vaccine were generally unaffected by the spike protein mutations in 
the beta variant.[9]
Examples of impact of COVID-19 
immunisation
Israel and the UK are countries with among the highest COVID-19 
vaccine coverage rates globally, at 61.6% and 55.2%, respectively, 
including ~85% of the adult population having been vaccinated. [1] 
The experience of the COVID-19 immunisation programme in 
these two countries, however, provides further evidence of the 
unlikelihood that herd immunity would materialise against COVID-
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19. Israel has exclusively used the BNT162b2 vaccine, which together 
with the Moderna and Novavax vaccines, induces the greatest fold 
increase in neutralising antibody responses after vaccination relative 
to antibody in convalescent sera (i.e. antibody in people recovering 
from COVID-19).[12.15]
Despite persistence of T-cell responses and IgG memory B-cells 
being evident at least 9 - 12 months after infection (and possibly 
also following vaccination),[18] significant declines in neutralising 
antibody are observed as early as 76 days after two doses of 
the BNT162b2 and AZD1222 vaccines.[19] Waning of neutralising 
antibody activity, coupled with a shift from the alpha to the more 
transmissible delta variant, could explain the decrease in effectiveness 
of the BNT162b2 vaccine in Israel. Soon after the introduction of 
the BNT162b2 vaccine in Israel, when the alpha variant mainly 
dominated, direct and indirect effects of vaccination were observed. 
In addition to BNT162b2 reducing the risk of hospitalisation by 
94% in Israel, vaccination also protected against any symptomatic 
COVID-19 (92 - 97% risk reduction) and asymptomatic illness (84% 
risk reduction),[20-22] and reduced infectiousness by 41 - 78%,[23,24] 
possibly owing to vaccinated individuals having lower viral loads. [25] 
These data boded well that rapid scale-up and high coverage with 
COVID-19 vaccines could lead to herd immunity.
Unfortunately, the emergence of the delta variant in Israel was 
associated with a resurgence of COVID-19, mainly presenting 
as mild illness.[1] Early estimates from Israel report that vaccine 
effectiveness against COVID-19 of any severity has waned from the 
initial 92 - 94% to 39%, albeit retaining 91% effectiveness against 
severe illness.[26] Factors contributing to the COVID-19 resurgence 
in Israel may include: (i) waning of vaccine-induced antibody over 
time; (ii) the delta variant being 40 - 60% more transmissible than the 
alpha variant that dominated early on in the vaccination programme, 
and possibly requiring a high concentration of neutralising antibody 
to protect against infection; and (iii) the delta variant being two-
fold less sensitive to vaccine-induced neutralising antibody relative 
to the ancestry virus or alpha variant. Also, these findings suggest 
that although IgG-producing memory B-cells may persist for at least 
9 - 12 months after natural infection,[18] mobilisation of these memory 
B-cells may not be timeous enough to protect against infection, even by 
variants relatively susceptible to vaccine-induced neutralising antibody 
activity. The Israeli experience attests to the challenges likely to be 
experienced in reaching and sustaining a herd immunity state, more 
so as SARS-CoV-2 is likely to undergo ongoing mutations that will be 
near to impossible to restrict to any geographical locality.
Similarly, in the UK, where the AZD1222 and BNT162b2 vaccines 
are mainly being deployed, despite high levels of vaccine coverage 
there has been a resurgence of COVID-19, also predominantly due 
to the delta variant (Fig. 1). The current COVID-19 wave in the UK 
is subsiding, having peaked at a lower level than experienced during 
the second wave, which occurred at an early stage of roll-out of the 
COVID-19 vaccine and was caused by the alpha variant, which 
is relatively less infectious than the delta variant.[1] It is possible 
that despite delta-variant breakthrough infections occurring after 
vaccination, immunity induced by the vaccines results in a lower viral 
load and duration of shedding. Such an effect of vaccines could assist 
in reducing virus transmission and attenuating the magnitude of future 
resurgences, even if it is not sufficient to achieve a herd immunity state.
Another feature of the current resurgences in the highly vaccinated 
Israeli and UK populations is the unhinging in trends of COVID-19 
cases and deaths compared with the earlier waves (Figs 2 and 3). The 
excess mortality in the UK was >100% and 40% of that expected at 
the time of the peak of the first and second waves, respectively. In 
contrast, excess deaths being experienced with the current outbreak 
are already subsiding in the UK and were only 5% above the historical 
average for the corresponding period (Fig. 2). Similarly, in Israel, 
where excess deaths attributable to COVID-19 were 40% above what 
was expected at the peak of the outbreak prior to COVID-19 vaccine 
roll-out, the current estimate for excess deaths in a population with 
high vaccine coverage is ~10% (Fig. 2).
The experience from both the UK and Israel emphasises that 
COVID-19 vaccines have greatest value in reducing the risk of severe 
The number of conrmed cases is lower than the number of actual cases, mainly because of limited testing. 
Note: Head-to-head comparisons across the wave and between countries are misleading owing to dierences in testing 
rates and criteria used for testing of suspected cases or infections.
Fig. 1. Daily COVID-19 cases per million population in Israel, the UK and South Africa (source: Our World in Data[1]).The rolling 7-day average is shown.
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Shown is how the number of weekly or monthly deaths in 2020 - 2021 dier as a percentage from the average number of deaths in the 
same period over the years 2015 - 2019. This metric is called the P-score. The reported number of deaths might not count all deaths that 
occurred, owing to incomplete coverage and delays in death reporting.
Fig. 2. Excess mortality during COVID-19: deaths from all causes compared with previous years, all ages in the UK and Israel (source: Our World in Data[1]).
Fig. 3. Daily new confirmed COVID-19 deaths per million population in South Africa, Israel and the UK (source: Our World in Data[1]). The rolling 7-day 
average is shown.
Note: Limited testing and challenges in the attribution of the cause of death mean that the number of conrmed deaths may not be an 
accurate count of the true number of deaths from COVID-19. Dierences in completeness of investigation of suspected COVID-19 cases, 
access to healthcare and reporting of deaths prevent head-to-head comparison between some countries.
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COVID-19 and death. In contrast, the magnitude of reported deaths 
in SA during the resurgence being experienced (i.e. third wave) 
due to the delta variant is likely to be similar to or exceed what was 
observed during the first or second waves (Fig. 3). This is partly 
a consequence of SA’s having only belatedly started to increase its 
COVID-19 vaccination rate, with 10.5% of the population having 
received at least a single dose by 2 August 2021.
Conclusions
In summary, although COVID-19 vaccines confer variable protec tion 
against infection and mild COVID-19, they have not interrupted 
virus transmission, particularly for the highly transmissible delta 
variant. Based on an R0 estimate of 6 for the delta variant, it is unlikely 
that any country could have a sustainable strategy for durable high 
level of protection against infection by the delta variant. Mutations of 
the SARS-CoV-2 genome are likely to continue resulting in enhanced 
transmissibility, infectiousness and resistance to neutralising activity 
of antibody induced by the current generation of COVID-19 vaccines.
The decision by the UK government to allow the opening up of 
society and learning to live with the virus had been made with the 
comfort of having excelled in ensuring that adults are protected 
through vaccination against what matters most, i.e. minimising the 
risk of severe COVID-19 and death, even with ongoing circulation 
of the virus. The UK approach seemingly concedes that the goal of 
herd immunity, even in a highly resourced setting, is unattainable. 
Furthermore, ongoing focus on aspiring to herd immunity by highly 
resourced countries comes at the cost of further exacerbating inequity 
that exists in the ability of LMICs to timeously access lifesaving 
COVID-19 vaccines. Recalibrating our expectations of COVID-19 
vaccines is long overdue, and ongoing promotion of booster doses of 
COVID-19 vaccines where they are least needed in the world, while 
millions are left susceptible to dying from COVID-19 because they 
are not able to access vaccines, is immoral.
Consequently, even in the unlikely scenario of vaccinating 84% 
of the total SA population, which would require vaccination of 
100% of individuals >12 years of age, achieving a herd immunity 
state with the current generation of COVID-19 vaccines is unlikely. 
Modelling based on antibody dynamics suggests that booster doses 
could be required every 2 - 3 years to protect against severe COVID-
19, and possibly every 6 - 9 months to protect against any SARS-
CoV-2 infection.[15] Sustaining repeat booster doses of COVID-19 
vaccination for the entire population every 2 - 3 years, let alone 
annually, is not pragmatic. This is particularly so in low-income 
countries, where just over 1% of the population has currently received 
a single dose of the 4 billion doses of COVID-19 vaccines that have 
been deployed to date, with the global average being 27% coverage 
with at least a single dose.[1]
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